FDA To Manufacturers: Describe Adverse Events More Fully
This article was originally published in The Silver Sheet
Executive Summary
FDA URGES FIRMS TO COMPLETE ADVERSE EVENT REPORT NARRATIVES so the agency will better understand the nature of the incident. Meanwhile, a new chart designed by CDRH's Office of Surveillance & Biometrics describes what FDA does with the reports it receives
You may also be interested in...
Transparency website aims to improve
After receiving 46 comments about its new transparency website, CDRH said it will implement certain recommendations to improve it. However, most responders to a survey on the website, launched April 19, said they found it to be very useful. The website now includes links to various device-related databases and the CDRH management directory, and includes information on topics such as health hazard evaluations and health risk assessments. It also recently added a chart that explains to manufacturers and patients how adverse events are processed by the agency. (See "1FDA To Manufacturers: Describe Adverse Events More Fully"
Speaking Of Medtech, Ep. 10: FDA’s TAP Pilot
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?